The DPM reports representative data in the form of more than 800 regularly updated charts, figures, and data tables. The DPM is based on a sample of over 4,000 patients in ~140 US dialysis units. It provides comparisons and trends over time (representative of the United States as a whole), using weighting techniques. Data are also provided by race and facility types. Research papers describing the DPM methods and findings have been published. Data are updated every four months, with only a three-to-four-month lag between data collection and Web posting.
The Prospective Payment System (PPS), an initiative of the Centers for Medicare & Medicaid Services (CMS) launched in January 2011, is intended to control dialysis costs through bundled payments (that is, fewer separately billable medications and services). The Quality Incentive Payment (QIP) program, which began in 2012, is the first Medicare program that links provider or facility payments to performance based on achievement of specific quality measures.
The DPM fills an important need, providing a source of timely, representative data, while tracking the effects of the ESRD PPS on dialysis practice. Its findings can serve as an early warning system for possible adverse effects on clinical care and as a basis for patient and dialysis community outreach, editorial comment, and informed advocacy.
DPM data are aggregated across dialysis organizations and facilities. Aggregated trends may not reflect trends in individual dialysis organizations or facilities, and are not intended to provide oversight of performance in individual dialysis organizations or facilities.
The Dialysis Outcomes and Practice Patterns Study (DOPPS) is a prospective cohort study investigating practices related to the best outcomes for hemodialysis patients in more than 20 countries. Administered by the nonprofit Arbor Research Collaborative for Health of Ann Arbor, Mich., the DOPPS is supported by research grants from Amgen (since 1996), Kyowa Hakko Kirin (since 1999, in Japan), Sanofi Renal (since 2009), AbbVie (since 2009), Baxter (since 2011), Vifor Fresenius Renal Pharma (since 2011), and Fresenius Medical Care North America (since 2012) without restrictions on publications. The DOPPS is based on patient- and facility-level data reported from nationally representative samples of facilities within each country. The DPM facility sample is nationally representative based upon recent analyses using CMS data that demonstrate similarity between the sample and the national data across the range of observed practice variation.
Click here to view the DOPPS Practice Monitor